Clinical Trials Sponsored by Jiangsu ShengDiYa Medicine Co., Ltd.

Total 1377 results

Jiangsu HengRui Medicine Co., Ltd.

Completed

Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis

Moderate-to-severe Chronic Plaque Psoriasis

United States, Australia, China
Jiangsu HengRui Medicine Co., Ltd.

Completed

To Compare the Pharmacokinetics and Pharmacodynamics of HR20014, INS068 and INS062 After Single Subcutaneous Injection in Healthy Subjects

Diabetes

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Effect of Omeprazole on the Pharmacokinetics of SHR6390 in Healthy Subjects

Advanced Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors

Advanced Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Drug-drug Interaction Study of Famitinib Malate With a Proton Pump Inhibitor in Healthy Adult Subjects

Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage

Primary Hypercholesterolemia | Mixed Hyperlipemia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Bioequivalence Study of Famitinib Malate in Healthy Volunteers Under Fasting Condition

Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

Breast Cancer | Triple Negative Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Efficacy and Safety of SHR8028 Eye Drops for the Treatment of Dry Eye Disease

Dry Eye Disease

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

SHR - 1209 Treatment Efficacy and Safety of the Patients With Hypercholesterolemia Ⅲ Period Clinical Research

Primary Hypercholesterolemia

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Hepatocellular Carcinoma (HCC)

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma

Advanced Melanoma

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

Advanced Biliary Tract Carcinoma | Advanced Primary Liver Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy (PASSION)

Small-cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects

HER2-positive Recurrent / Metastatic Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell Neoplasmstumor

Mature B Cell Neoplasms

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Bioavailability Study of SHR1459 on Healthy Chinese Volunteers

Healthy Adult Subjects

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Phase 2 Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects.

Diabetes Mellitus, Type 2

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors

Neoplasm Malignant | Tumor, Solid | Cancer, Metastatic

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer

HER2 Positive Metastatic Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

SHR9549 in ER Positive HER2 Negative Advanced Breast Cancer

ER+ HER2- Advanced Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Clinical Study of Remimazolam Tosilate in Patients Undergoing Bronchoscopy

Sedation

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR4010 in Patients With Hemodialysis

Pruritus

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment

Hepatic Impairment

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia （SAA） Patient

Severe Aplastic Anemia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Pharmacokinetic Interaction Study Between Apatinib and Rosuvastatin or Metformin in Solid Tumor Subjects.

Solid Tumor, Adult

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects

Nasopharyngeal Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of Abiraterone in Combination With SHR3162 in the Treatment of mCRPC

Prostate Cancer Castration-resistant Prostate Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of HR071603(Ketamine Nasal Spray) in Healthy Subjects

Depression

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Food Effect Study of DDO-3055 Tablets in Healthy Subjects

Anemia in Chronic Kidney Disease

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

Extensive-stage Small Cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of HRS4800 Tablets for Postoperative Analgesia After Impacted Teeth Removal Surgery.

Pain

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC

Non-small Cell Lung Cancer(NSCLC)

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers

Human Immunodeficiency Virus Infection

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects

Healthy Subjects

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors

Advanced Solid Tumors

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Trial of Hetrombopag in Healthy Subjects

Sever Aplastic Anaemia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study on the Bioavailability of SHR0302 in Healthy Subjects

Healthy Subjects

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Pharmacokinetics and Safety of SHR0302 in Patients With Hepatic Impairment

Hepatic Impairment

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study to Investigate Relative Bioavailability of Different Formulations of SHR6390 in Healthy Subjects

Healthy Volunteers

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study of SHR0302 Tablets (SHR0302) as Monotherapy in Active Rheumatoid Arthritis (RA) Patients

Rheumatoid Arthritis

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

The Single, Multiple Dose and Food Effect Study of SHR2285 Tablets on Pharmacokinetics and Pharmacodynamics in Healthy Subjects

Thrombosis

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Acute Vulvovaginal Candidiasis

Acute Vulvovaginal Candidiasis

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study to Evaluate SHR-1210 in Combination With Capecitabine + Oxaliplatin Sequenced by SHR-1210 + Apatinib as First-line Therapy in Treatment of Advanced Gastric Cancer

Gastric Cancer | GastroEsophageal Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Trial of HR021618 in Postsurgical Pain Management

Postsurgical Pain Management

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

HR021618 in Moderate to Severe Pain After Abdominal Surgery

Pain After Abdominal Surgery

China
Jiangsu HengRui Medicine Co., Ltd.

Withdrawn

A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study to Evaluate the Mass Babance and Biotransformation of [14C]SHR6390 in Healthy Adult Male Volunteers

Healthy Adult Male Volunteers

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Drug-Drug Interaction of Pyrotinib With a Moderate CYP3A Inducer

Healthy Subjects, Drug-drug Interaction, Pyrotinib

China

3

Subscribe